A Review Of Paniculoside I
All enrolled patients who been given not less than a person dose of zosuquidar or placebo all through induction were monitored to the prevalence of adverse activities (439 clients, 219 on zosuquidar and 210 on placebo). The commonest adverse situations were relevant to the duration of extended and sizeable myelosuppression as is expected with induc